Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Stephane Bancel

At a glance: Stephane Bancel is CEO at Moderna (MRNA). Their latest SEC Form 4, filed Aug 7, 2026, reported a sale of $8.3M. On file: 0 purchase lines ($0) and 4 sale lines ($28.7M).

Disclosed holdings: about $1.24B of MRNA stock: 6,187,791 shares reported on their latest Form 4 (filed Aug 7, 2026), valued at the Nov 19, 2026 close of $200.20. This counts only MRNA shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO at Moderna, Inc. (MRNA)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $28.7M

Stephane Bancel's InsiderPrint

5 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.

InsiderPrint of Stephane Bancel: 5 trades, 2025 to 20262025: 1 buy, 0 sales2026: 0 buys, 4 sales

Reading this print: Mostly sells, trading about 4 times a year, typically $7.1M a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (1)
  • Dent inward: a sale (4)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Nicholas A.J. BotwoodHead Of R&D, Cmo · SNDX · 96% match
  2. Ryan CorbettCFO · MP · 95% match
  3. Clarence L. GrangerDirector · UCTT · 95% match
  4. Lara PoloniPresident · ACM · 95% match
  5. James C. Fish Jr.Director · CAT · 95% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2025

From the SEC's insider data sets: each open-market buy by Stephane Bancel, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -14.0% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
MRNAMar 4, 2025-14.0%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Aug 7SEC MRNAModerna, Inc. Sell Plan 147,4736,539,564 held (−2%) $56.21 $8.3M +256.2%
Aug 7SEC MRNAModerna, Inc. Sell Plan 124,8386,414,726 held (−2%) $56.96 $7.1M +251.5%
Aug 7SEC MRNAModerna, Inc. Sell Plan 39,8916,374,835 held (−1%) $58.12 $2.3M +244.5%
Aug 7SEC MRNAModerna, Inc. Sell Plan 187,0446,187,791 held (−3%) $58.79 $11.0M +240.5%
  • Sell

    CEO Stephane Bancel sold $8.3M of MRNA at $56.21 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO Stephane Bancel sold $7.1M of MRNA at $56.96 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO Stephane Bancel sold $2.3M of MRNA at $58.12 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO Stephane Bancel sold $11.0M of MRNA at $58.79 — pre-scheduled 10b5-1 plan sale.

Follow Stephane Bancel

Get one email when Stephane Bancel files a new purchase or sale. Free.

At most one email a day about Stephane Bancel, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.